Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
Part of paid clinical trials in Memphis, Tennessee.
- Sponsor
- St. Jude Children's Research Hospital
- Study ID
- NCT02775643
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 18 Years
- Healthy Volunteers
- Not accepted
Study Details
This is an observational, non-therapeutic study to collect clinical and molecular information of pediatric patients with childhood melanocytic lesions. PRIMARY OBJECTIVE: To perform a comprehensive molecular analysis of samples either from paraffin embedded and/or frozen tissue from patients with pediatric melanocytic lesions (including melanoma, spitzoid melanoma, congenital melanoma, melanoma arising in giant nevi). SECONDARY OBJECTIVE: To collect minimal information on patients treated with adjuvant or systemic therapies according to National Comprehensive Cancer Network (NCCN) guidelines.
Key Dates
- Start date
- May 31, 2016
- Status verified
- Nov 2025
- Primary completion
- May 31, 2031
- Completion
- May 31, 2041
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Genomic profile [ Time Frame: At participant enrollment ]
Central Contacts
- Alberto Pappo, MD866-278-5835
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Alberto Pappo, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Memphis, TN
By condition
By specialty
By research site
Related Studies
- Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of TreatmentRecruiting · Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPHASE1/PHASE2 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Clovis, California